Fenwick Represents Aeglea BioTherapeutics in its Initial Public Offering

​​Fenwick & West represented Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism and cancer, in its initial public offering of 5,481,940 shares of its common stock at an initial public offering price of $10.00 per share, which included the partial exercise by the underwriters of their option to purchase an additional 481,940 shares of common stock.

UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities acted as joint book-running managers for the offering. Needham & Company acted as co-manager.

The Fenwick transaction team included corporate lawyers Robert Freedman, Effie Toshav, Matthew Rossiter, Niki Fang, Melissa Frayer and Chris Gorman.